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ONLINE SUPPLEMENT  
 
Study visit schedule 
At 12 weeks (primary end point) and 24 weeks, participants and carers from both the intervention and 
control groups were reviewed in clinic by the study team and recent treatments and hospital/healthcare 
utilisation, medication use, participant and carer HRQoL and mood, satisfaction with care documented. 
A summary of the visit and data collection schedule is provided in table 1.  
 
Telephone consultations with participants in both the intervention and control group were performed at 
4, 8, 16 and 20 weeks to review recent treatments and healthcare utilisation, medication use, HRQoL 
questionnaires. After participant death, the carer was approached by the study team to complete the final 
questionnaires, 24 weeks after bereavement.  
 
Table 1. Summary of the study visit and data collection schedule. QLQ-C30 = (EORTC) Quality of Life 
questionnaire Core 30; GHQ-12 = General Health Questionnaire-12; SF-36 = short form 36 health survey. 

















✓ ✓ ✓ ✓ ✓ ✓ ✓ 
 
GHQ-12 (participant) ✓   ✓   ✓  
GHQ-12 (caregiver) ✓   ✓   ✓ ✓ 
SF-36 (caregiver) ✓   ✓   ✓ ✓ 
FAMCARE-2 
(caregiver) 





Exploratory Analysis  
 
Symptom burden using the EORTC QLQ-C30 and LC13. A chi2 test was performed for each of the 
questions to compare the numbers who answered Quite a Bit/ Very Much vs Not at All/ A Little 






Recruitment by centre is presented in Table 2. 
 
Table 2. List of centres recruiting to the study. All centres are based in England with the exception 
of Sir Charles Gairdner Hospital  
 Regular Early 
Specialist Palliative 
Care (N=87) 
Standard Care (N=87) 
Centre:   
Basildon and Thurrock University Hospitals NHS 
Foundation Trust 
4 (4.6)  3 (3.5) 
Broomfield Hospital, Mid Essex Hospital NHS Trust 2 (2.3) 2 (2.3)  
Ipswich Hospital NHS Trust 2 (2.3)  1 (1.2)  
Kings Mill Hospital, Sherwood Forest Hospitals 
NHS Foundation Trust 
2 (2.3) 2 (2.3) 
Musgrove Park, Taunton and Somerset NHS 
Foundation Trust 
3 (3.5) 2 (2.3) 
County Durham and Darlington NHS Foundation 
Trust   
3 (3.5) 2 (2.3) 
North Manchester General Hospital, Pennine Acute 
Hospitals NHS Trust 
5 (5.8)  5 (5.8)  
North Tyneside General, Northumbria Healthcare 
NHS Foundation Trust 
1 (1.2) 1 (1.2) 
Sir Charles Gairdner Hospital, Perth, Australia 18 (20.7) 18 (20.7)  
South Tyneside NHS Foundation Trust 4 (4.6) 1 (1.2) 
University Hospital Southampton NHS Foundation 
Trust 
1 (1.2) 2 (2.3) 
Southmead Hospital, North Bristol NHS Trust 4 (4.6) 3 (3.5) 
Basingstoke and North Hampshire Hospital - 
Hampshire Hospitals NHS Foundation Trust  
0 (0.0) 1 (1.2) 
Great Western Hospitals NHS Foundation Trust 3 (3.5) 0 (0.0) 
New Cross Hospital, The Royal Wolverhampton 
NHS Trust 
0 (0.0) 1 (1.2) 
Norfolk & Norwich University Hospitals NHS 
Foundation Trust 
3 (3.5)  6 (6.9) 
Queen Alexandra Hospital, Portsmouth Hospitals 
NHS Trust 
17 (19.5)  18 (20.7) 
Royal Hampshire County Hospital, Hampshire 
Hospitals NHS Foundation Trust 
5 (5.8)  3 (3.5)  
Wythenshawe Hospital, University Hospital of 
South Manchester NHS Foundation Trust  
9 (10.3)  13 (14.9) 
Wansbeck General, Northumbria Healthcare NHS 
Foundation Trust 





Table 3. Reported symptoms from EORTC QLQ-C30 and EORTC QLQ-LC13 at week 12. For each 
question: n=no. of responses received, 0= 1 Not at All or 2 A Little; 1= 3 Quite a Bit or 4 Very Much 
 
 Early Specialist 
Palliative Care 
Standard Care  Chi2(1) P-value  
EORTC QLQ-C30 
Q8: Were you short of breath? n= 150 




48/25 (65.8/34.2)  
0.95 
Q9: Have you had pain? n= 150  
0/1 (%0/1)  
n=77 
66/11 (85.7/14.3)  
n=73 
58/15 (79.5/20.5)  
0.31 
Q18: Were you tired? n=148  
0/1 (%0/1) 
n=76 
47/29 (61.8/38.2)  
n=72 
45/27 (62.5/37.5)  
0.93 
EORTC QLQ-LC13 
Q33: Were you short of breath when you 







Q34: Were you short of breath when you 







Q35: Were you short of breath when you 
climbed stairs? n=145  
0/1 (%0/1) 
n=73 



















Table 4. Pre-specified sub group analyses using the Global Health Status of the EORTC QLQ-C30 quality of life questionnaire. GHS = Global Health 
Status; NLR = Neutrophil to lymphocyte ratio; IASLC = International Association for the Study of Lung Cancer; AUS = Australia; UK = United 
Kingdom; ECOG = European Collaborative Oncology Group; SD = standard deviation; CI = confidence intervals  
 
GHS score on the EORTC QLQ-C30 for participants at 12 weeks  
 Neutrophil/ 
lymphocyte ratio (<5/≥5)  




Age at baseline 
(<75/≥75) 
















Standard care Early 
Specialist 
palliative care 
Standard care Early 
Specialist 
palliative care 













59.5 (21.2) 60.2  
(23.6) 



















(n=114):   
-0.31  
(-8.0, 7.3) 











(-18.7, 15.9)  













(-5.1, 23.0)  


















0.52 0.51 0.24 1.00 0.47 0.69 
GHS score on the EORTC QLQ-C30 for participants at 24 weeks 













63.7 (19.8) 61.3  
(20.7) 
63.7 (19.8)  61.3  
(20.7)  














(n=96):   
-0.2  
(-7.8, 7.3) 






(-17.3, 2.7)  



































P-Value  for 
interaction 
0.70 0.38 0.38 0.90 0.16 0.83 
 5 
Table 5. Baseline characteristics of study participants with data for the primary analysis (n=148).  
 Early Specialist Palliative 
Care (n=75) 




 n=     
Age median (LQ, UQ) 75 72.0 (66.4, 77.0) 73 72.8 (68.9, 78.1) 0.01 
Gender Male (%)  75 58 (77.3) 73 60 (82.2) 0.90 
Neutrophil to Lymphocyte Ratio 
Median (LQ, UQ)  
75  3.5 (2.7, 5.1) 72 3.9 (2.7, 6.8) 0.02 
Minimisation factors:      
Plan for chemotherapy Yes (%) 75 40 (53.3) 72 38 (52.8) 0.94 




















UQ = upper quartile; LQ = lower quartile; ECOG = Eastern Collaborative Oncology Group  
1This column compares patients with the primary outcome (n=148) vs patients missing the primary 
outcome (n=26). For each baseline factor, the number of patients with available baseline data out of 148 
with the primary outcome is shown in the table i.e. n (sum of both arms), the number of patients with 
available baseline data out of 26 missing the primary outcome is n (sum of both arms) in Table2 minus n 
(sum of both arms) shown here.   
 
 
Table 5 shows that the randomised groups are well-balanced for baseline characteristics. P-values are 
shown for comparing those included vs excluded from the primary analysis, the mean age for those 
missing the primary outcome was higher which was to be expected but this does not cause an imbalance 
between treatment groups in patients with available primary outcome. Similarly, there are some 
differences in neutrophil to lymphocyte ratio and histological subtype between those with and without 
the primary outcome but the balance between treatment groups was unaffected.  
 
 
Figure 1  
CONSORT diagram of the full study period (24 weeks), including carers 
 
Figure 2 
Kaplan Meier graph of overall survival by treatment arms censored at the last known date of contact in the study 
 
